Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9467)	11/12/2003 12:04:59 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

I opened a starter position in MYGN today. Their r-flubiprofen program has little safety risk (it's an enantiomer of a fairly widely used NSAID that apparently SEPR missed in its rummaging around). There's pretty good evidence that the drug reduces Abeta42, so the big unanswered question is the role of Abeta42 in AD prevention/treatment. There are certainly strong hints from studies of NSAIDS that some NSAIDS have an effect on AD, although Naprosyn (Alleve) struck out, which is consistent with the Abeta42 hypothesis. The stock is not real expensive at these levels, and there's big upside if it pans out. (PR in next post because of SI problems) Peter